Michael B. Lilly
Impact in
- Pathology and Forensic Medicine top 0.5%
- Cancer Mechanisms and Therapy
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments
Papers in
- Oncology 36
- Peptidase Inhibition and Analysis 15
- Co-authors
- Andrew S. Kraft (16 shared papers)Marina Zemskova (10 shared papers)Päivi J. Koskinen (3 shared papers)Jouko Sandholm (2 shared papers)Sheldon L. Holder (4 shared papers)Harri Mankonen (1 shared paper)Katriina Peltola (1 shared paper)Matthew R. Janes (4 shared papers)
- Journals
- Journal of Clinical Oncology (16 papers)Blood (6 papers)Journal of Biological Chemistry (5 papers)Oncotarget (3 papers)Molecular Cancer Therapeutics (3 papers)
- Partner nations
- United StatesChinaSingapore
In The Last Decade
Michael B. Lilly
101 papers receiving 4.4k citations
Peers
Comparison fields: 5 of 125
- Pathology and Forensic Medicine 1.4k
- Hematology 593
- Oncology 1.2k
- Cancer Research 507
- Molecular Biology 2.2k
Countries citing papers authored by Michael B. Lilly
This map shows the geographic impact of Michael B. Lilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael B. Lilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael B. Lilly more than expected).
Fields of papers citing papers by Michael B. Lilly
This network shows the impact of papers produced by Michael B. Lilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael B. Lilly. The network helps show where Michael B. Lilly may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael B. Lilly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 105 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 277 | |
| 2 | 2010 | 277 | |
| 3 | 2012 | 266 | |
| 4 | 2003 | 216 | |
| 5 | 2004 | 188 | |
| 6 | 2007 | 159 | |
| 7 | 1999 | 146 | |
| 8 | 2005 | 131 | |
| 9 | 2008 | 128 | |
| 10 | 2008 | 126 | |
| 11 | 2008 | 110 | |
| 12 | 2009 | 109 | |
| 13 | 2009 | 101 | |
| 14 | 2020 | 99 | |
| 15 | 2012 | 87 | |
| 16 | 2009 | 85 | |
| 17 | 2015 | 83 | |
| 18 | Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. | 1997 | 83 |
| 19 | 2010 | 76 | |
| 20 | Local hyperthermia with interstitial techniques. | 1984 | 76 |
About Michael B. Lilly
Michael B. Lilly is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Cancer Research, having authored 105 papers that have together received 4.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (27 papers), Cancer Mechanisms and Therapy (17 papers), Peptidase Inhibition and Analysis (15 papers), Cancer Genomics and Diagnostics (11 papers), Chronic Myeloid Leukemia Treatments (8 papers), Multiple Myeloma Research and Treatments (6 papers), Immune Response and Inflammation (6 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.4k citations), Hematology (593 citations), Oncology (1.2k citations), Cancer Research (507 citations) and Molecular Biology (2.2k citations). Michael B. Lilly has collaborated with scholars based in United States, China and Singapore. Frequent co-authors include Andrew S. Kraft, Marina Zemskova, Päivi J. Koskinen, Jouko Sandholm, Sheldon L. Holder, Harri Mankonen, Katriina Peltola, Matthew R. Janes, Eva Sahakian and I Brezovich. Their work appears in journals such as Journal of Clinical Oncology, Blood, Journal of Biological Chemistry, Oncotarget and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.